ArticleJournal of medicinal chemistry2021
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.
Abstract read
In one paragraph
Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Substrate-Guided Engineering of Imine Reductases: A Strategy for Synthesizing Tertiary Amine N-Heterocycles.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Isoniazid-rhodanine molecular hybrids: design, synthesis, antimycobacterial activity and computational validation.RSC advances · 2025Article
- Challenging the Biginelli scaffold to surpass the first line antitubercular drugs:Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Agrochemical Lessons for Infectious Disease Research: New Resistance Breaking Antifungal Hits againstACS medicinal chemistry letters · 2023Article
- Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre.ACS medicinal chemistry letters · 2022Article
- Polyfluoroalkylated antipyrines in Pd-catalyzed transformations.RSC advances · 2021Article
- Strategies to Combat Multi-Drug Resistance in Tuberculosis.Accounts of chemical research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Candice Soares de MeloDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Vinayak SinghDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-9002-2489
Alissa MyrickDrug Discovery and Development Centre (H3D), University of Cape Town, Rondebosch 7701, South Africa.
Sandile B SimelaneDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Dale TaylorDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.
Christel BrunschwigDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.
Nina LawrenceDrug Discovery and Development Centre (H3D), Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa.
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
Curtis A EngelhartDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
Anuradha KumarInfectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.
Tanya ParishInfectious Disease Research Institute, 1616 Eastlake Ave E, Suite 400, Seattle, Washington 98102, United States.ORCID 0000-0001-7507-0423
Qin SuGenomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Timothy G MyersGenomic Technologies Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Helena I M BoshoffTuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.ORCID 0000-0002-4333-206X
Clifton E BarryTuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
Frederick A SirgelSouth African Medical Research Council Centre for Tuberculosis Research/DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, Stellenbosch University, Tygerberg 7505, South Africa.
Paul D van HeldenSouth African Medical Research Council Centre for Tuberculosis Research/DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Science, Stellenbosch University, Tygerberg 7505, South Africa.
Kirsteen I BuchananDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Tracy BaylissDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Simon R GreenDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.ORCID 0000-0001-5054-4792
Peter C RayDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Paul G WyattDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.ORCID 0000-0002-0397-245X
Gregory S BasarabDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0001-5684-6046
Charles J EyermannDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Kelly ChibaleDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-1327-4727
Sandeep R GhorpadeDrug Discovery and Development Centre (H3D), Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID 0000-0002-9311-1572
Funding
Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1MDevelopment Of New Chemotherapeutics For TuberculosisZIAAI000693 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2025
$20.1MWellcome Trust 203134/Z/16/Z
Abstract
Phenotypic screening of a Medicines for Malaria Venture compound library against
Indexed as
AnimalsAntitubercular AgentsBacterial ProteinsHalf-LifeHumansIronMaleMembrane Transport ProteinsMiceMice, Inbred C57BLMicrobial Sensitivity TestsMicrosomesMutationMycobacterium tuberculosisPyrazolesPyrimidinonesAntitubercular AgentsBacterial ProteinsIronMembrane Transport ProteinsMmpL3 protein, Mycobacterium tuberculosisPyrazolesPyrimidinones
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.